Advertisement
| bristol myers squibb car t therapy: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| bristol myers squibb car t therapy: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| bristol myers squibb car t therapy: Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2016-12-10 Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop. |
| bristol myers squibb car t therapy: Principles and Practice of Palliative Care and Supportive Oncology Ann M. Berger, John L. Shuster, Jr., Jamie H. Von Roenn, 2012-12-03 Unlike other textbooks on this subject, which are more focused on end of life, the 4th edition of Principles and Practice of Palliative Care and Supportive Oncology focuses on supportive oncology. In fact, the goal of this textbook is to provide a source of both help and inspiration to all those who care for patients with cancer. Written in a more reader-friendly format, this textbook not only offers authoritative and up-to-date reviews of research and clinical care best practices, but also practical clinical applications to help readers put everything they learn to use. |
| bristol myers squibb car t therapy: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| bristol myers squibb car t therapy: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| bristol myers squibb car t therapy: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| bristol myers squibb car t therapy: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| bristol myers squibb car t therapy: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| bristol myers squibb car t therapy: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| bristol myers squibb car t therapy: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| bristol myers squibb car t therapy: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| bristol myers squibb car t therapy: Report to the Congress, Medicare Payment Policy Medicare Payment Advisory Commission (U.S.), 1998 |
| bristol myers squibb car t therapy: Economic Dimensions of Personalized and Precision Medicine Ernst R. Berndt, Dana P. Goldman, John Rowe, 2019-04-22 Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement of PPM is a challenge in traditional clinical, reimbursement, and regulatory landscapes because it is costly to develop and introduces a wide range of scientific, clinical, ethical, and socioeconomic issues. PPM raises a multitude of economic issues, including how information on accurate diagnosis and treatment success will be disseminated and who will bear the cost; changes to physician training to incorporate genetics, probability and statistics, and economic considerations; questions about whether the benefits of PPM will be confined to developed countries or will diffuse to emerging economies with less developed health care systems; the effects of patient heterogeneity on cost-effectiveness analysis; and opportunities for PPM’s growth beyond treatment of acute illness, such as prevention and reversal of chronic conditions. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. |
| bristol myers squibb car t therapy: Mechanisms of Drug Toxicity H. Rašková, 2013-10-22 Mechanisms of Drug Toxicity, Volume 4 presents the proceedings of the 3rd International Pharmacological Meeting held in Sao Paulo, Brazil in 1966. The book discusses the drug-induced pathobiotic effects; the mechanisms of adverse reactions; and enzyme induction in the mechanism of chronic toxicity. The text also describes the influence of inducing substances on the growth of liver and microsomal electron transport systems; the quantitative aspects of chronic toxicity; and the facts and fallacies in predicting drug effects in human. |
| bristol myers squibb car t therapy: Cutaneous Melanoma Charles M. Balch, Michael B. Atkins, Claus Garbe, Jeffrey E. Gershenwald, Allan C. Halpern, John M. Kirkwood, Grant A. McArthur, John F. Thompson, Arthur J. Sober, 2020-01-29 Written by the leading melanoma experts from the United States, Australia, and Europe, this new edition incorporates the clinical outcomes of more than 70,000 patients treated at major melanoma centers throughout the world and is the definitive and most authoritative textbook on melanoma used worldwide. Providing the most up-to-date and comprehensive information needed for the clinical management and scientific study of melanoma, Cutaneous Melanoma, 6th edition covers everything from precursors of melanoma to advanced stages of metastatic disease. |
| bristol myers squibb car t therapy: Onco-Nephrology E-Book Kevin W. Finkel, Mark Anthony Perazella, Eric P Cohen, 2019-07-02 Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed. - Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy. - Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer. - Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment. - Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care. - Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies – treatments that are being recognized for adverse kidney effects. - Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| bristol myers squibb car t therapy: Kidney Cancer Primo N. Lara, Eric Jonasch, 2015-06-10 Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recent developments in kidney cancer diagnosis and therapy. The user-friendly and clinically oriented content of the book guarantees that it will be of great interest to a wide range of medical professionals, and every effort has been made to ensure that contributions are both easy to understand and directly related to patient care. Content presentation departs from the usual dense chapter format featuring a lengthy series of paragraphs. Instead, each chapter contains several boxed sections, including one that summarizes essential take home points for the busy clinician and another that presents a patient-oriented case highlighting the clinical application of elements discussed in that chapter. In addition, accessible original images, illustrations, and diagrams (some in full color) are used to simplify particularly complex material. This book will be of value for clinicians, researchers, residents, fellows, students, and knowledgeable lay people. The contributors comprise an international group of authors with expertise in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others. |
| bristol myers squibb car t therapy: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| bristol myers squibb car t therapy: Digital Economy. Emerging Technologies and Business Innovation Rim Jallouli, Mohamed Anis Bach Tobji, Deny Bélisle, Sehl Mellouli, Farid Abdallah, Ibrahim Osman, 2019-09-20 This book constitutes the refereed proceedings of the 4th International Conference on Digital Economy, ICDEc 2019, held in Beirut, Lebanon, in April 2019. The conference was founded in 2016 to discuss innovative research and projects related to the support role of Information System Technologies in the digital transformation process, business innovation and e-commerce. The 31 papers presented in this volume were carefully reviewed and selected from 89 submissions. The theme of ICDEc 2019 was “Digital Economy: Emerging Technologies and Business Innovation”. The papers were organized in topical sections named: digital transformation; e-finance; social media communication; intelligent systems; e-commerce and business analytics; e-learning and cloud education; e-commerce and digital economy; data science; digital marketing; and digital business model. |
| bristol myers squibb car t therapy: Axial Spondyloarthritis Philip Mease, Muhammad Asim Khan, 2019-02-16 Focusing on the key essentials you need to know, Axial Spondyloarthritis provides a quick, expert overview of axSpA from a clinical perspective. This concise resource by Drs. Philip Mease and Muhammad Khan presents practical recommendations and guidelines for the diagnosis, management, and treatment of spondyloarthritis impacting the axial skeleton alongside an overview of epidemiology, special populations, and patient education. - Discusses key information on genetic factors and disease biomarkers. - Presents an overview of clinical features, classification criteria, and imaging to aid in diagnosis. - Covers management and treatment guidelines, including non-pharmacologic management and the use of biologics. - Consolidates essential information on this timely topic into a single, convenient resource. |
| bristol myers squibb car t therapy: Brain Tumor Immunotherapy Linda M. Liau, Donald P. Becker, Timothy F. Cloughesy, Darell D. Bigner, 2000-11-10 An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics. |
| bristol myers squibb car t therapy: Computational Modeling of Gene Regulatory Networks Hamid Bolouri, 2008 This book serves as an introduction to the myriad computational approaches to gene regulatory modeling and analysis, and is written specifically with experimental biologists in mind. Mathematical jargon is avoided and explanations are given in intuitive terms. In cases where equations are unavoidable, they are derived from first principles or, at the very least, an intuitive description is provided. Extensive examples and a large number of model descriptions are provided for use in both classroom exercises as well as self-guided exploration and learning. As such, the book is ideal for self-learning and also as the basis of a semester-long course for undergraduate and graduate students in molecular biology, bioengineering, genome sciences, or systems biology. |
| bristol myers squibb car t therapy: The Comprehensive Cancer Center Mahmoud Aljurf, Navneet S. Majhail, Mickey B.C. Koh, Mohamed A. Kharfan-Dabaja, Nelson J. Chao, 2021-10-28 This open access book provides a valuable resource for hospitals, institutions, and health authorities worldwide in their plans to set up and develop comprehensive cancer care centers. The development and implementation of a comprehensive cancer program allows for a systematic approach to evidence-based strategies of prevention, early detection, diagnosis, treatment, and palliation. Comprehensive cancer programs also provide a nexus for the running of clinical trials and implementation of novel cancer therapies with the overall aim of optimizing comprehensive and holistic care of cancer patients and providing them with the best opportunity to improve quality of life and overall survival. This book's self-contained chapter format aims to reinforce the critical importance of comprehensive cancer care centers while providing a practical guide for the essential components needed to achieve them, such as operational considerations, guidelines for best clinical inpatient and outpatient care, and research and quality management structures. Intended to be wide-ranging and applicable at a global level for both high and low income countries, this book is also instructive for regions with limited resources. The Comprehensive Cancer Center: Development, Integration, and Implementation is an essential resource for oncology physicians including hematologists, medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses as well as hospitals, health departments, university authorities, governments and legislators. |
| bristol myers squibb car t therapy: Innovations in Development, Translational Research and Manufacturing of CAR T cells Michael Hudecek, Qasim Rafiq, Stephen Goldrick, Ulrike Koehl, Helene Negre, Carmen Sanges, 2024-10-03 Immunotherapy with genetically engineered immune cell products is a transformative treatment modality with potential applications in various fields of medicine. A prime example is chimeric antigen receptor (CAR)-modified T cells in hematology and oncology, and the advent of CAR T cell therapies to treat infectious diseases, autoimmune disorders, and cardiovascular diseases. The medical need and demand from patients and caregivers require radical innovations to accelerate and improve pre-clinical development and clinical translation, provision of gene-transfer vectors, and immune cell product manufacturing as well as a critical reflection and discussion on ethical and socioeconomic aspects. The goal of this special issue of Frontiers in Immunology is to provide a comprehensive and multi-faceted view on the current state-of-the-art, imminent and future directions the field is taking in order to accelerate the pre-clinical development, clinical translation, and manufacturing of CAR T cells, increase access and sustainability of CAR T cell therapy for health care systems (in developed and in developing countries). This special issue will focus on the medical and scientific dimension incl. approved and emerging indications, new areas in medicine, advanced gene-transfer and gene-editing technologies, innovations in pre-clinical assessment (efficacy, toxicology, genomic safety), innovations in scalable automated manufacturing (bioprocessing), the implementation of high content data acquisition, machine learning and artificial intelligence, innovations in clinical trial design; and consider the ethical, socioeconomic and societal dimension of CAR T cells in particular and gene-engineered immune cell therapy in general. |
| bristol myers squibb car t therapy: Understanding and Managing Oncologic Emergencies Marcelle Kaplan, 2018 Thoroughly updated and expanded, the third edition of Understanding and Managing Oncologic Emergencies: A Resource for Nurses is a comprehensive yet practical guide to understanding and managing oncologic emergencies from the nursing perspective. |
| bristol myers squibb car t therapy: High-Risk Cutaneous Squamous Cell Carcinoma Chrysalyne D. Schmults, 2016-04-29 This book is a cutting-edge resource that provides clinicians with the up-to-date practical knowledge required in order to manage SCC patients optimally. It summarizes newly available information relating to the definition of high-risk SCC, its pathophysiologic underpinnings, and its management. New prognostic information and staging systems are summarized that enable high-risk tumors to be defined more precisely than ever before. Many helpful tips are provided on the practical management of challenging cases, including multiple tumors/field cancerization, high-risk tumors, nodal metastases, and unresectable disease. The authors are all acknowledged experts in the emerging field of high-risk and advanced SCC. |
| bristol myers squibb car t therapy: Management of Hematologic Malignancies Susan O'Brien, Julie M. Vose, Hagop M. Kantarjian, 2010-11-18 Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology. |
| bristol myers squibb car t therapy: The Breakthrough Charles Graeber, 2015-12-01 Follow along as this New York Times bestselling author details the astonishing scientific discovery of the code to unleashing the human immune system to fight in this captivating and heartbreaking book (The Wall Street Journal). For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold? As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses -- tricks that scientists have only recently discovered and learned to defeat. The result is what many are calling cancer's penicillin moment, a revolutionary discovery in our understanding of cancer and how to beat it. In The Breakthrough, New York Times bestselling author of The Good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step -- harnessing the wealth of new information to create modern and more effective patient therapies -- is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease. Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history. |
| bristol myers squibb car t therapy: Translational Research in Breast Cancer Dong-Young Noh, Wonshik Han, Masakazu Toi, 2021-05-13 This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to the bench for basic research, as well as findings that have been applied back to the bedside. Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer. |
| bristol myers squibb car t therapy: Molecular Hematology Drew Provan, Hillard M. Lazarus, 2024-03-05 Provides a core knowledgebase for those with minimal exposure to hematologic molecular biology, fully revised and updated Molecular Hematology brings together the most up-to-date and reliable information on the molecular basis of major hematologic diseases. Edited and authored by leading experts in the field, this volume demonstrates the clinical relevance of molecular biology in the diagnosis and treatment of blood disorders. Concise, accessible chapters address key topics in modern hematology, such as lymphoma genetics, molecular coagulation, thrombophilia, pharmacogenomics, platelet disorders, hemophilia, anemia, and multiple myeloma. Chapters introduce and summarize specific hematologic diseases, explore the pathogenesis of the disorder, highlight new and emerging molecular strategies, and more. Now in its fifth edition, Molecular Hematology is fully revised to incorporate contemporary hematology research and practice. Entirely new chapters cover topics such as CAR-T cell technology, COVID, cancer cell biology, gene therapy and gene editing in clinical practice, as well as the impact of molecular research on the diagnosis and treatment of various malignant hematologic diseases. This edition includes updated suggested readings and a wealth of new full-color charts, graphs, and illustrations throughout. Covers the molecular biology of different blood diseases, their pathogeneses, and current molecular research and therapies Illustrates the impact of molecular research on hematologic investigations and therapeutics Discusses how progress in basic science and therapeutics has improved the diagnosis and care of patients with various hematologic disorders Surveys recent developments in cancer-cell biology, with an emphasis on leukemia and lymphoma Includes access to a companion Digital Edition providing search across the book, downloadable illustrations, and notation tools Molecular Hematology is a must-have resource for established and trainee clinicians, clinical scientists and researchers, medical students, and upper-level undergraduates in the fields of hematology, oncology, and molecular biology. |
| bristol myers squibb car t therapy: New Frontiers in Gene-Modified T Cell Technology Ignazio Caruana, Francesca Del Bufalo, Rayne Rouce, Shigeki Yagyu , Paul G. Schlegel, 2024-06-13 The development, clinical translation and recent efficacy of novel gene therapies targeting refractory malignancies has led to research that extends this technology to a variety of infectious and rheumatological diseases. Unlike conventional drugs or antibodies, T cells have the potential to target and exert effector function in response to disease in a dynamic manner, acting as a “living drug”. The most efficacious form of gene-modified T cells to date is the chimeric antigen receptor (CAR)-modified T cell, which redirects the specificity of T cells to an antigen expressed by tumor cells. Clinical experience with autologous CAR-T cells, primarily in hematologic malignancies, has underscored the feasibility and safety of the approach, while also demonstrating dramatic and sustained antitumor effects through mechanisms orthogonal to those of traditional anticancer therapies. However, several challenging obstacles must be surmounted in order to improve the broader efficacy of this approach. |
| bristol myers squibb car t therapy: Emerging Engineering Approaches in Cancer Immunotherapy Xin Ming, Yuanzeng Min, Chao Wang, Yueyin Pan, 2022-10-06 |
| bristol myers squibb car t therapy: Critical Developments in Cancer Immunotherapy Sheykhhasan, Mohsen, Yang, Piao, Poondla, Naresh, 2024-08-28 Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment. |
| bristol myers squibb car t therapy: American Society of Hematology Self-Assessment Program Timothy Graubert, James R. Cook, Laura Scheuttpelz, Donald M. Arnold, Adam Cuker, Cindy Neunert, Keith R. McCrae, Margaret Ragni, Sarah O'Brien, Murat Arcasoy, Gary Lyman, Marc J. Kahn, Lawrence A. Solberg, Jecko Thachil, Timothy James Littlewood, Sioban Keel, Charles T. Quinn, Charles H. Packman, Stephan Moll, David Garcia, David P. Steensma, Anjali Sharathkumar, Jorge Di Paola, Amy D. Shapiro, A. Koneti Rao, Charles Eby, Jacob Rand, John Frater, Karen Quillen, Suzanne Bakdash, Dan S. Kaufman, David T. Scadden, Jerald Radich, Sergio Giralt, Geoffrey L. Uy, Inderjeet Dokal, Ross Levine, Ramon V. Tiu, Phillip Scheinberg, Lillian Sung, B. Douglas Smith, Daniel J. DeAngelo, Ching-Hon Pui, Kristie A. Blum, Ann LaCasce, Kerry Joanne Savage, Brad S. Kahl, Grzegorz S. Nowakowski, Vicki A. Morrison, Irene Ghobrial, Martha Lacy, 2013-06-04 Hematologists and others working in hematology-related fields need to stay current with the latest advances in the rapidly evolving disciplines of adult and pediatric hematology. The American Society of Hematology Self-Assessment Program (ASH-SAP) is the only complete, comprehensive, educational resource available that fulfills this need, while also providing thorough board and recertification preparation, as well as AMA PRA Category 1 Credit'. |
| bristol myers squibb car t therapy: Precision Cancer Therapies, Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies Owen A. O'Connor, Stephen M. Ansell, John Gribben, 2024-04-29 Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject. |
| bristol myers squibb car t therapy: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| bristol myers squibb car t therapy: Telephone Triage for Otorhinolaryngology and Head-neck Nurses Cindy Dawson, Margaret Hickey (RN.), 2011 Provide efficient patient assessments over the telephone with this handy reference! As healthcare delivery continues to shift from a predominantly inpatient setting to ambulatory care, telephone triage has become an increasingly important competency for nurses to master, especially for those working with patients with otorhinolaryngology issues. Telephone Triage for Otorhinolaryngology and Head-Neck Nurses provides symptom-specific guidelines, to handle patients' common concerns. Cindy J. Dawson, Margaret M. Hickey, and Susan Newton have brought together nurses who specialize in otorhinolaryngology and head-neck care to share their expertise for 38 suggested symptom protocols, including special considerations for pediatric patients. Chapters on triage models, tips on performing triage, how to conduct an assessment over the telephone, and legal concerns round out the book for a complete resource. This text can serve as a handy guide for telephone triage training, as well as establishing a formal telephone triage nursing program within an otorhinolaryngology practice. When patients call, Telephone Triage for Otorhinolaryngology and Head-Neck Nurses provides valuable information at your fingertips. Book jacket. |
| bristol myers squibb car t therapy: Development of Gene Therapies Avery McIntosh, Oleksandr Sverdlov, 2024-05-23 Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community . Key Features: A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts. An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways. An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx. Insights into commercial models, access hurdles, and health economics of gene therapies. Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma. A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective. |
| bristol myers squibb car t therapy: Next-Generation Cancer Therapies based on a (R)evolution of the Biomarker Landscape Claudia Cerella, Katia Aquilano, Marc Diederich, Anne Lorant, 2022-03-30 |
Understanding the CAR T Cell Therapy Treatment - Bristol …
Chimeric antigen receptor (CAR) T cell therapy is a personalized approach to treating certain blood cancers. Unlike traditional cancer therapies, autologous CAR T cell therapies are often …
CAR T Cell Therapy for Patients with Autoimmune Disease
Autologous chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy that reprograms T cells to express a CAR that binds to a specific antigen on target cells, leading to …
CAR-T Therapy - ECPC
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell …
Analytical Comparability for Autologous CAR-T Products
Autologous CAR T Cell Therapy Product At Bristol Myers Squibb. In the pipeline: https://www.bms.com/researchers-and-partners/in-the-pipeline.html. Key Cell Therapy Product …
[ACT]IVATED CAR T-CELL THERAPY CHECKLIST
Prepare Questions: Write down any questions/concerns you have about CAR T-cell therapy and its significance in myeloma treatment. Research Local Resources: Identify nearby healthcare …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy equips a patient’s T cells with the ability to detect and destroy malignant cells by combining the specificity of a monoclonal antibody with the cytotoxic and memory …
Benefit Verification Checklist - Cell Therapy 360
Benefit verification (BV) with a patient’s payer is critical to help identify specific considerations for each appropriate patient for Bristol Myers Squibb CAR T cell therapies. Treatment centers …
Delivering progress on a cellular level - Bristol Myers Squibb
Our CD19-directed CAR T cell therapy is an important option for patients with a broad array of relapsed/refractory B cell-mediated lymphomas. To date, more than 10,000 patients have …
Cigna Lifesource Transplant Network
Criteria for contracting: 1. Approved CAR -T program for commercial products; 2. Associated hematopoietic stem cell transplant program currently contracted in the Cigna LifeSOURCE …
The Potential Role of CAR-T Cell Therapy in Multiple Sclerosis
(BCMA) CAR-T cell therapy can cross the blood–brain barrier and may allow for a deep but non-sustained B cell depletion with immune reset. Efficacy and safety results
CAR T 102: Introduction to the Patient Cell Therapy Journey
General considerations for CAR T cell therapy: Have a disease as defined in commercial indication or in clinical trial 1 Adequate marrow and organ function, as well as patient fitness and
Cell Therapy - Bristol Myers Squibb
• CAR T cell therapy – CAR T cell therapy reprograms a patient’s T cells (a specific type of immune cell) to attack cancer – T cells are engineered to express a protein that recognizes …
Bristol Myers Squibb Car T Therapy Copy - old.icapgen.org
the implementation and management of CAR T cell therapy from Drs Daniel W Lee and Nirali N Shah this clinical resource keeps you up to date on the latest developments in this rapidly …
BMS cell therapy operations and manufacturing
Bristol Myers Squibb is advancing the field of cell therapy through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of …
Understanding the CAR T Cell Therapy Treatment_030824_JK
Chimeric antigen receptor (CAR) T cell therapy is a personalized approach to treating certain blood cancers. Unlike traditional cancer therapies, autologous CAR T cell therapies are often …
Outpatient Monitoring - car-t-academy.com
•Every CAR T cell therapy program requires the ability to: —Safely administer CAR T cell therapy1 —Properly monitor and manage patients before, during, and following treatment2 …
19/22 - Bristol Myers Squibb
Bristol Myers Squibb is committed to building a leadership position in cell therapy by leveraging unparalleled disease expertise, CMC capabilities, manufacturing scale and portfolio of …
Patient Evaluation in CAR T Therapy - CAR T Academy
Considerations for CAR T Cell Therapy 6 01: Patient Evaluation General considerations for candidates for CAR T cell therapy: • Have a disease as defined in commercial indication or in …
Bridging Therapy and Lymphodepleting Chemotherapy - CAR …
CAR T Academy Summary Bridging therapy —Some patients may receive bridging therapy while CAR T cell therapy is being manufactured —The purpose is to maximize disease control and …
Bristol Myers Squibb Highlights Advancing Pipeline and …
• Potential first cell therapy targeting GPRC5D, our CAR T BMS-986393, starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). • BCMA x CD3 T-cell engager, …
Understanding the CAR T Cell Therapy Treatment - Bristol …
Chimeric antigen receptor (CAR) T cell therapy is a personalized approach to treating certain blood cancers. Unlike traditional cancer therapies, autologous CAR T cell therapies are often …
CAR T Cell Therapy for Patients with Autoimmune Disease
Autologous chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy that reprograms T cells to express a CAR that binds to a specific antigen on target cells, leading to …
CAR-T Therapy - ECPC
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell …
Analytical Comparability for Autologous CAR-T Products
Autologous CAR T Cell Therapy Product At Bristol Myers Squibb. In the pipeline: https://www.bms.com/researchers-and-partners/in-the-pipeline.html. Key Cell Therapy Product …
[ACT]IVATED CAR T-CELL THERAPY CHECKLIST
Prepare Questions: Write down any questions/concerns you have about CAR T-cell therapy and its significance in myeloma treatment. Research Local Resources: Identify nearby healthcare …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy equips a patient’s T cells with the ability to detect and destroy malignant cells by combining the specificity of a monoclonal antibody with the cytotoxic and memory …
Benefit Verification Checklist - Cell Therapy 360
Benefit verification (BV) with a patient’s payer is critical to help identify specific considerations for each appropriate patient for Bristol Myers Squibb CAR T cell therapies. Treatment centers …
Delivering progress on a cellular level - Bristol Myers Squibb
Our CD19-directed CAR T cell therapy is an important option for patients with a broad array of relapsed/refractory B cell-mediated lymphomas. To date, more than 10,000 patients have …
Cigna Lifesource Transplant Network
Criteria for contracting: 1. Approved CAR -T program for commercial products; 2. Associated hematopoietic stem cell transplant program currently contracted in the Cigna LifeSOURCE …
The Potential Role of CAR-T Cell Therapy in Multiple Sclerosis
(BCMA) CAR-T cell therapy can cross the blood–brain barrier and may allow for a deep but non-sustained B cell depletion with immune reset. Efficacy and safety results
CAR T 102: Introduction to the Patient Cell Therapy Journey
General considerations for CAR T cell therapy: Have a disease as defined in commercial indication or in clinical trial 1 Adequate marrow and organ function, as well as patient fitness and
Cell Therapy - Bristol Myers Squibb
• CAR T cell therapy – CAR T cell therapy reprograms a patient’s T cells (a specific type of immune cell) to attack cancer – T cells are engineered to express a protein that recognizes …
Bristol Myers Squibb Car T Therapy Copy - old.icapgen.org
the implementation and management of CAR T cell therapy from Drs Daniel W Lee and Nirali N Shah this clinical resource keeps you up to date on the latest developments in this rapidly …
BMS cell therapy operations and manufacturing
Bristol Myers Squibb is advancing the field of cell therapy through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of …
Understanding the CAR T Cell Therapy Treatment_030824_JK
Chimeric antigen receptor (CAR) T cell therapy is a personalized approach to treating certain blood cancers. Unlike traditional cancer therapies, autologous CAR T cell therapies are often …
Outpatient Monitoring - car-t-academy.com
•Every CAR T cell therapy program requires the ability to: —Safely administer CAR T cell therapy1 —Properly monitor and manage patients before, during, and following treatment2 …
19/22 - Bristol Myers Squibb
Bristol Myers Squibb is committed to building a leadership position in cell therapy by leveraging unparalleled disease expertise, CMC capabilities, manufacturing scale and portfolio of …
Patient Evaluation in CAR T Therapy - CAR T Academy
Considerations for CAR T Cell Therapy 6 01: Patient Evaluation General considerations for candidates for CAR T cell therapy: • Have a disease as defined in commercial indication or in …
Bridging Therapy and Lymphodepleting Chemotherapy
CAR T Academy Summary Bridging therapy —Some patients may receive bridging therapy while CAR T cell therapy is being manufactured —The purpose is to maximize disease control and …
Bristol Myers Squibb Highlights Advancing Pipeline and …
• Potential first cell therapy targeting GPRC5D, our CAR T BMS-986393, starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). • BCMA x CD3 T-cell engager, …
